Skip to main content
IntegraGen logo

IntegraGen — Investor Relations & Filings

Ticker · ALINT ISIN · FR0010908723 LEI · 969500CQD8K0BUIGDH55 PA Professional, scientific and technical activities
Open in API
Filings indexed 160 across all filing types
Latest filing 2014-12-02 Regulatory Filings
Country FR France
Listing PA ALINT

About IntegraGen

https://integragen.com/

IntegraGen, an OncoDNA company, specializes in translating molecular research into clinical practice, with a primary focus on cancer genomics and rare genetic diseases. The company provides comprehensive genomic services, including Next-Generation Sequencing (NGS) and advanced bioinformatics analysis, to academic researchers, biopharmaceutical companies, and clinical research organizations. Operating from a CLIA/CAP-certified laboratory, IntegraGen is a key genomics partner for oncology clinical trials. Its core mission involves identifying novel genetic biomarkers to develop and commercialize molecular diagnostic tests, delivering interpretable genomic data to advance both research and patient care.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE – POUR DIFFUSION IMMÉDIATE" (Press Release - For Immediate Release) and announces a specific business event: IntegraGen obtaining worldwide license rights for two molecular signatures related to liver cancer from Inserm Transfert and Université PARIS DESCARTES. This is a corporate announcement detailing a strategic agreement, licensing deal, and intellectual property acquisition. This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV), best fits the category for corporate actions or significant business updates that don't have a more specific code. Since it is a press release announcing a major business development (licensing/IP acquisition), it is most appropriately classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially a Capital/Financing Update (CAP) if the deal involved immediate financing, but the core is the IP transaction. Given the options, RNS serves as the best fit for a general corporate press release detailing a strategic agreement that isn't explicitly covered by other codes like M&A (TAR) or Share Issue (SHA). It is not an ER, IR, or AR. It is a specific business transaction announcement.
2014-12-02 French
Rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT SEMESTRIEL au 30 juin 2014' (Half-Year Report as of June 30, 2014). It contains detailed financial statements (income statement, balance sheet data), management's discussion and analysis of the period's activities, and operational highlights. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2014
2014-10-31 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Interim / Quarterly Report Classification · 95% confidence The document is a press release from IntegraGen announcing its financial results for the first half of 2014. It contains detailed financial statements, including a profit and loss account and a balance sheet, and provides management commentary on business performance. While it is formatted as a press release, it includes the substantive financial data required for an interim report. Therefore, it is classified as an Interim / Quarterly Report (IR). H1 2014
2014-10-07 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – POUR DIFFUSION IMMÉDIATE" (Press Release - For Immediate Release). It announces the presentation of scientific data (biomarker predictive value for cancer treatment) at a medical conference (ESMO 2014). This format—a brief announcement summarizing recent findings or events, often referencing external publications or presentations—is characteristic of a general press release or news item rather than a formal regulatory filing like a 10-K, IR, or ER. Since it is a press release announcing scientific/clinical progress and not a formal financial report, dividend notice, or management change, the most appropriate classification among the provided options is the general regulatory/news fallback category, RNS (Regulatory Filings), as it serves as a general corporate announcement not covered by more specific codes like DIV, ER, or MANG. The length (5467 chars) is substantial enough to be a full press release, not just a short RPA.
2014-09-30 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – POUR DIFFUSION IMMEDIATE" (Press Release – For Immediate Release). It announces a collaboration between IntegraGen and IFCT regarding research into a biomarker (miR-31-3p) for non-small cell lung cancer. This type of announcement, detailing business developments, partnerships, and research progress, is characteristic of a general corporate announcement rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a specific financial report (IR, AR). Since it is a press release announcing a business development, and there is no specific category for general press releases, the most appropriate fallback category is Regulatory Filings (RNS), which often serves as a catch-all for important, non-standardized corporate communications released to the public/market, especially when the content is not a formal financial statement or proxy material. The length (5248 chars) is substantial enough that it is not merely an announcement *of* a report, but the report itself (the press release).
2014-09-02 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 95% confidence The document is explicitly titled "IntegraGen – Chiffre d'affaires du 1er semestre 2014" (Revenue for the first half of 2014) and provides key financial figures (revenue of 2.6 M€) for a six-month period ending June 30, 2014. It also mentions that the company "publiera ses résultats semestriels le 24 octobre 2014" (will publish its semi-annual results on October 24, 2014). This content strongly indicates a summary or initial announcement of interim financial results, fitting the definition of an Earnings Release (ER) or an Interim Report (IR). Since it focuses on key revenue figures and highlights rather than being the comprehensive 'résultats semestriels' themselves (which are announced for October), it aligns best with an Earnings Release (ER). However, given the explicit mention of 'semestre' (half-year) results, the Interim Report (IR) category is also highly relevant. Since this is a press release summarizing the H1 performance, ER is often used for the initial release, while IR is the comprehensive filing. Given the structure and the forward-looking statement about the full results publication, ER is the most appropriate classification for this immediate announcement. H1 2014
2014-07-16 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.